Measurement of serum anti-GLA antibodies in Fabry patients received ERT and their phenotype and genotype.

1)Aga-A; agalsidase alpha 2)Aga-B; agalsidase beta 3)IC; immunochromatography 4)OD; optical density at 450nm 5)Score: 8 scale-values of line density by visual measurement 6)ERT; enzyme replacement therapy 7)NA; not available 8)WT: wild type. Each serum was diluted 100 folds and 5 folds with healthy control serum before ELISA and IC, respectively. 8)Cont: average values of healthy control (Refer to S1 Table). Measurement of serum anti-GLA antibodies in Fabry patients received ERT and their phenotype and genotype.1) Aga-A：阿加糖酶α（agalsidase alpha） 2) Aga-B：阿加糖酶β（agalsidase beta） 3) IC：免疫层析法（immunochromatography） 4) OD：450nm光密度（optical density at 450nm） 5) 评分：目视法测定的8级条带密度分值 6) ERT：酶替代疗法（enzyme replacement therapy） 7) NA：不可用（not available） 8) WT：野生型（wild type）。每份血清分别以健康对照血清稀释100倍、5倍，分别用于酶联免疫吸附实验（ELISA）与免疫层析法（IC）检测。 8) Cont：健康对照的平均值（详见附表S1）。 本数据集用于检测接受酶替代疗法（ERT）的法布雷病患者血清抗GLA抗体水平，并分析其表型与基因型。